Dr Decotiis on New Study:Ozempic/Semaglutide Reduces Kidney Failure Risk by 20% in Diabetes Patients

Dr Decotiis on New Study:Ozempic/Semaglutide Reduces Kidney Failure Risk by 20% in Diabetes Patients
Lines tonight for its promising success in treating kidney disease. This is according to a new study published in the New England Journal of Medicine Today, and it found weekly injections of semaglutide drugs like Ozempic could slash the risk of kidney failure and death by 20% for those with type two diabetes and chronic kidney disease. This study was funded by Novo Nordisk, which makes Ozempic. It's now asking the FDA to expand the drug's use to include chronic kidney disease, and more than 35 million Americans are living with kidney disease. This follows a report last week that found patients who had been taking Ozempic or its sister drug Wegovy, for weight loss, successfully kept the pounds off after four years and they had a reduced risk of heart disease. But questions remain, largely because it is so relatively new. It was approved for medical use in this country just seven years ago. Joining us now with more is doctor Sue Decotiis, who specializes in weight loss and hormone therapy. A doctor. We appreciate your time and tell us why this study is such a big deal, because it seems kidney disease is very common for people with diabetes. About 1 in 3 people with diabetes impacted by kidney disease. Could this be life changing for millions of people?
Yes, this could really be life changing. I mean, kidney disease is one of the worst things that anyone can have. It's very progressive, especially in a diabetic, and usually within a couple of years, someone can wind up either on dialysis or needing a kidney transplant. And when someone goes on dialysis, their risk of cardiovascular disease goes up like 50%. There's a very, very high chance they're going to die of a heart attack or stroke. So it's they're losing weight, they're controlling their diabetes. And I think by virtue of the fact that we are regulating the way insulin works, and insulin is a hormone that really helps improve kidney function by increasing blood flow to the kidney. So it's really never been a better time to be in weight loss medicine at such a fantastic time, because we're really able to help patients like never before.
I. Certainly in my lifetime I've never quite seen a medication like this that has so many. It seems like magic bullet applications. And I do want to ask, you know, Novo Nordisk did fund this trial. They obviously have a lot to gain with these results. Every time this expands to another issue, should we have any questions about the objectivity, the way that this trial was conducted?
I don't believe so. I mean, I think they want to do well and they know they have a great drug. And a previous study about a year ago also showed the same thing. Um, and I'm really not concerned about too many long term. I practice in Manhattan. I see a wide range of patients in the tri state area and all over the country, and I've really never had anybody have some of these horrible side effects, you know, like pancreatitis or or thyroid cancer or anything like this. The GI side effects are usually pretty minimal. But I will say this as far as treatment goes, I think sometimes we're missing the boat about not emphasizing how important it is, as if a patient is losing weight, that we really monitor their body composition. We have to be sure that they're losing fat and not muscle. A patient that loses muscle is going to be at increased risk for many different problems. They're really kind of glad that you're bringing this away. They're not going to be healthy. And one way tell me muscle wasting is hydration. And that's often something that patients are not being told to do. So in my practice, I'm if any of my patients are watching, I'm sure they're rolling their eyes right now. I'm always telling them, drink a tremendous amount of water, especially on the highest doses. And that also goes for those patients that are taking Mounjaro or z-band, which is tirzepatide, not just semaglutide, which is ozempic and wegovy. So that's really, really important.
That's really interesting and I'm glad you bring this up. So if someone were not to be on a semaglutide and you know, when they lose weight, the muscle wasting is something that we really see with semaglutide that we wouldn't see normally with, with just normal, drastic weight loss, is that right? It's increased.
Well, it can happen with both. So what happens is the body burns fat as the body is burning fat on these drugs.
Sue Decotiis, MD
20 E 46th St., #1201
New York, NY 10017
Phone: [phone]
www.drdecotiis.com/ozempic-semaglutide-mounjaro-tirzepatide-weight-loss-doctor-manhattan-nyc
#Ozempic #Mounjaro #Wegovy #Semaglutide #WeightLoss #WeightLossDoctor #NYC #DR #MD #News
#NewsNation
#KidneyHealth
#DiabetesManagement
#ChronicKidneyDisease
#MedicalResearch
#HealthStudy
#HormoneTherapy
#WeightLossMedication
#MedicalResearch
#HealthStudy
#NovoNordisk

[@VernCrisler]

Ouch, did the reporter say sim-EYE gloo-tide? I believe sema in semaglutide probably has reference to the term "week," or 7 days, as in a weekly dose. BTW, the reason Novo Nordisk funded this is because these large corporations are the only ones who can afford to do these large-scale trials. They still have to go through FDA testing and not all drugs survive this testing process. So, I agree with Dr. Decotiis -- there's no reason to deny the objectivity of these trials.